Karahocagil, M. KasimBuzgan, TuranIrmak, HasanKarsen, HasanAkdeniz, HayrettinAkman, Nevzat2025-05-102025-05-1020060886-022X10.1080/088602206008400412-s2.0-33750086933https://doi.org/10.1080/08860220600840041https://hdl.handle.net/20.500.14720/12417Karahocagil, Mustafa Kasim/0000-0002-5171-7306; Buzgan, Turan/0000-0001-7897-3660This study compared the application of intramuscular recombinant hepatitis B vaccine in hemodialysis patients with the application of accelerated intradermal recombinant hepatitis B vaccine, which can be applied with one-tenth of the standard dose. Sixty seronegative patients for hepatitis B were randomly separated into two groups. Twenty mu g of the recombinant hepatitis B vaccine was intramuscularly applied at 0-, 1-, 2-, and 6-month intervals to the first group (32 cases). One more dose was applied at month 12 to those whose anti-HBs titers remained below 100 mIU/mL at month 7. The same vaccine was intradermally applied at 2 mu g dose six times with one-month intervals to the second group (28 cases). Vaccine applications were continued in those whose anti-HBs titers remained below 100 mIU/mL at month 7 until antibody titers reached above this value or until the dose number became 12. Measurements of antibody titers were repeated at month 13 in both groups. As a result, in the vaccination of hemodialysis patients against hepatitis B, the accelerated ID application of hepatitis B vaccine with a dose reduced to one-tenth is more cost-effective than the standard dose vaccination schedules. Especially for hemodialysis patients, the time has come for routine application of ID hepatitis B vaccine as an alternative vaccination method.eninfo:eu-repo/semantics/closedAccessHepatitis B VaccinationIntradermal VaccinationHemodialysisArticle287Q2Q256156517035164WOS:000241185400007